Miltefosine for Mucosal Leishmaniasis

AB Foundation

Status and phase: Completed; Phase 2; Phase 1

Conditions: Leishmaniasis

Treatments: Drug: miltefosine 2.5 mg/kg/day for 28 days

Study type: Interventional

Funder types: Other

Identifiers

NCT00373776

04--01

Details and patient eligibility

About

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Full description

Treat bolivian mucosal leishmaniasis with miltefosine.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mucosal leishmaniasis

Exclusion criteria

• Abnormal liver function tests (LFT)
• Abnormal kidney function test
• Concomitant diseases

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)